JNJ-81241459, JNJ-81241459 200mg, placebo tablet, JNJ-81241459, JNJ-81241459 50mg, placebo tablet
Phase 2 small_molecule active
Quick answer
JNJ-81241459, JNJ-81241459 200mg, placebo tablet, JNJ-81241459, JNJ-81241459 50mg, placebo tablet for Plaque Psoriasis is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Plaque Psoriasis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active